Global Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in emerging markets and developing countries. This book provides you with a practical approach to recognizing the opportunities and tackling the challenges that are present during the planning and execution of global clinical trials for Alzheimer’s disease. Written by leading experts with hands-on experience in designing and running global Alzheimer’s disease and other neurodegenerative diseases clinical trials A step-by-step guide that provides critical information on the design, conduct and standardization necessary to effectively execute clinical trials and accelerate drug development in this area Includes practical examples, ethical considerations, lessons learned and other valuable tools to aid the planning and implementation of Alzheimer’s disease global clinical trials in emerging markets and developing countries

Produk Detail:

  • Author : Menghis Bairu
  • Publisher : Academic Press
  • Pages : 432 pages
  • ISBN : 0124115306
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKGlobal Clinical Trials for Alzheimer s Disease

Global Clinical Trials for Alzheimer's Disease

Global Clinical Trials for Alzheimer's Disease
  • Author : Menghis Bairu,Michael Weiner
  • Publisher : Academic Press
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer's Disease

Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in

Global Clinical Trials for Alzheimer’s Disease

Global Clinical Trials for Alzheimer’s Disease
  • Author : James (Dachao) Fan,Li Huafang,Jing Yin
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer’s Disease

China has the largest number of people with dementia and the incidence is projected to increase much faster than in the developed world. There is a great demand for new drugs that can prevent or treat the disease and great potential for conducting Alzheimer’s disease clinical trials. The majority of Alzheimer’s disease trials that have been conducted in China are local trials. In early years, there were deficiencies in trial design and implementation; however, with more attention from

Global Clinical Trials for Alzheimer’s Disease

Global Clinical Trials for Alzheimer’s Disease
  • Author : Yağız Üresin,Hilal İlbars,İbrahim Hakan Gürvit,Murat Emre
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer’s Disease

Turkey straddles the continents of Europe and Asia, and this unique geographical location steers its economy. On the world economic scale, as an exceptional emerging economy, Turkey is the 16th largest economy in the world and the sixth largest economy as compared with the European Union countries, according to gross domestic product. The Turkish pharmaceutical sector is ranked 16th in terms of market value, and it is 36th in terms of the clinical research conducted and the volume of pharmaceutical

Global Clinical Trials for Alzheimer’s Disease

Global Clinical Trials for Alzheimer’s Disease
  • Author : Michel Grothe,Jens Kurth,Harald Hampel,Bernd J. Krause,Stefan Teipel
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer’s Disease

In-vivo imaging markers of neuronal changes related to Alzheimer’s disease (AD) are ideally suited to be employed as diagnostic markers for early and differential diagnosis of AD as well as for the assessment of neurobiological effects of medical treatments in clinical trials. Novel molecular imaging techniques enable in-vivo detection of cerebral amyloid pathology, whereas magnetic resonance imaging (MRI)-based techniques, such as volumetric MRI and diffusion tensor imaging (DTI), provide structural lesion markers that allow tracking disease progression from

Global Clinical Trials for Alzheimer’s Disease

Global Clinical Trials for Alzheimer’s Disease
  • Author : Jeffrey Cummings,Kate Zhong
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer’s Disease

Globalization is increasingly common as a means of more rapidly recruiting patients, shortening clinical trials, abbreviating clinical development cycle times, and preparing for marketing in non-US markets. Globalization refers to the inclusion of trial sites in three or more international regions. Globalization is common and most drug development programs include both US and non-US sites. There has been limited evaluation of the transnational performance of clinical trial instrumentation used in drug development programs. The performance across nations, languages and cultures

Global Clinical Trials for Alzheimer’s Disease

Global Clinical Trials for Alzheimer’s Disease
  • Author : Tal Burt,Lynne Hughes,Amir Kalali,P. Murali Doraiswamy
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer’s Disease

There is considerable interest, both nationally and internationally, in conducting dementia research in India. Motivated by a rapid increase in the aging population and a desire for indigenous, self-sufficient healthcare and medical research, dementia research in India is on course for rapid growth in the coming years. Several challenges will have to be overcome along the way. A solid and general clinical research culture and a supportive healthcare system, both tailored to the specific needs of the dementia field and

Global Clinical Trials for Alzheimer’s Disease

Global Clinical Trials for Alzheimer’s Disease
  • Author : H. Michael Arrighi
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer’s Disease

Alzheimer’s disease (AD) confers an additional risk of death. The magnitude of this impact is related to the person’s underlying mortality and current AD stage. When planning clinical trials, estimating the number of deaths prior to study initiation, and periodically during the study as participants are enrolled, assists in providing an informative context, particularly if there are few life events. Additionally, deaths have the potential to introduce a bias, thus, equal follow-up needs to ensure for participants assigned

Global Clinical Trials for Alzheimer’s Disease

Global Clinical Trials for Alzheimer’s Disease
  • Author : Hans J. Möbius
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer’s Disease

Regulatory approval of the first rational AD therapeutic tacrine occurred in 1993, followed by the approval of three other, AChEIs, and the NMDA antagonist memantine in 2002 (EMA) and 2003 (FDA) respectively. Since then, despite an enormous research and development effort, the past 10 years have seen a series of failures to translate pathophysiological understanding of dementia into new medicines. This includes a move away from neurotransmission to a focus on underlying pathological processes. The major reason for these failures was probably the continued

Global Clinical Trials for Alzheimer’s Disease

Global Clinical Trials for Alzheimer’s Disease
  • Author : Roy W. Jones
  • Publisher : Elsevier Inc. Chapters
  • Release : 28 August 2013
GET THIS BOOKGlobal Clinical Trials for Alzheimer’s Disease

Current drug treatments for Alzheimer’s disease (AD) appear to be symptomatic. There is an increasing priority to find effective and safe disease-modifying and preventive treatment strategies for cognitive decline, AD, and dementia. Recent developments have allowed the identification of possible pathogenic processes and pathways, and potential targets for intervention. Cerebrospinal fluid (CSF) biomarkers of ß-amyloid and tau, and neuroimaging including amyloid PET tracer retention show that the pathogenic process begins many years before symptoms appear. A number of preventive

Evidence-based Dementia Practice

Evidence-based Dementia Practice
  • Author : Nawab Qizilbash,Lon S. Schneider,Henry Brodaty,Pierre Tariot,Jeffrey Kaye,Helena Chui,Timo Erkinjuntti
  • Publisher : John Wiley & Sons
  • Release : 15 April 2008
GET THIS BOOKEvidence-based Dementia Practice

The era of therapeutic nihilism in dementia has ended, with the emergence of agents for symptomatic treatment, those that delay the course of the disease or prevent the onset of dementia, and new methods to manage symptoms. With the expansion of therapies, there is a clear danger of being overwhelmed by the volume of data. This book is designed to collect this information, distil what is relevant and reliable, and present it in a format that is useful to clinicians

Developing Therapeutics for Alzheimer's Disease

Developing Therapeutics for Alzheimer's Disease
  • Author : Michael S. Wolfe
  • Publisher : Academic Press
  • Release : 27 May 2016
GET THIS BOOKDeveloping Therapeutics for Alzheimer's Disease

Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the

Neurodegenerative Dementias

Neurodegenerative Dementias
  • Author : Christopher Clark,John Q. Trojanowski
  • Publisher : Appleton & Lange
  • Release : 09 March 2021
GET THIS BOOKNeurodegenerative Dementias

Presents a logical and elegant review of basic science, diagnosis, and treatment of the most heavily researched and most commonly encountered group of devastating neurologic illnesses: the neurodegenerative dementias.

Public Engagement and Clinical Trials

Public Engagement and Clinical Trials
  • Author : Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation
  • Publisher : National Academies Press
  • Release : 17 March 2012
GET THIS BOOKPublic Engagement and Clinical Trials

Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a